Cardiovascular damage phenotypes and all-cause and CVD mortality in older adults

Lindsay M Miller1, Chenkai Wu2, Calvin H Hirsch3

  • 1Division of Nephrology-Hypertension, University of California San Diego, La Jolla, CA; School of Biological and Population Health Sciences, Oregon State University, Corvallis, OR.

Annals of Epidemiology
|August 2, 2021
PubMed

Insights

Identifying distinct cardiovascular damage phenotypes in older adults is crucial. The multisystem morbidity phenotype showed the highest risk for all-cause and cardiovascular mortality, highlighting the danger of widespread disease.

Area of Science:

  • Gerontology
  • Cardiovascular Medicine
  • Biostatistics

Background:

  • Cardiovascular disease (CVD) risk factors are linked to mortality, but current assessments often overlook subgroup variations.
  • Understanding specific combinations of risk factors may illuminate underlying physiological mechanisms of morbidity and mortality in elderly populations.

Purpose of the Study:

  • To identify distinct cardiovascular (CV) damage phenotypes in older adults using latent class analysis (LCA).
  • To evaluate the association between these identified CV damage phenotypes and all-cause and CVD-mortality.

Main Methods:

  • Latent class analysis (LCA) was used to define CV damage phenotypes in 5067 older adults from the Cardiovascular Health Study.
  • Phenotypes were based on probabilities of abnormalities in brain infarctions, echocardiogram, N-terminal probrain natriuretic peptide, troponin T, interleukin-6, c-reactive protein, galectin-3, and cystatin C.
  • Cox-proportional hazards regression analyzed the link between categorical CV damage phenotypes and mortality outcomes.

Main Results:

  • Five CV damage phenotypes were identified: healthy (59%), cardio-renal (11%), cardiac (15%), multisystem morbidity (6%), and inflammatory (9%).
  • All non-healthy phenotypes were associated with increased all-cause mortality risk compared to the healthy phenotype.
  • The multisystem morbidity phenotype exhibited the highest risk for all-cause mortality (HR: 4.02) and CVD-mortality (HR: 4.90).

Conclusions:

  • Five distinct CV damage phenotypes were identified in older adults.
  • Multisystem CV damage significantly increases mortality risk compared to single-domain damage.
  • These phenotypes offer a refined approach to understanding mortality risk in older populations.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
537
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
51
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
38
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
30
The Effect of Aging on Tissues01:19

The Effect of Aging on Tissues

Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
2.9K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
97